lenalidomide has been researched along with Leukemia, Lymphocytic, Chronic, B-Cell in 137 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 22 (16.06) | 29.6817 |
| 2010's | 105 (76.64) | 24.3611 |
| 2020's | 10 (7.30) | 2.80 |
| Authors | Studies |
|---|---|
| Arcangeli, S; Banerjee, P; Barbaglio, F; Bertilaccio, MTS; Biagi, E; Biondi, A; Caligaris-Cappio, F; Galletti, G; Gandhi, V; Ghia, P; Giordano Attianese, GMP; Ivan, C; Keating, M; Martinelli, G; Mazza, M; McManus, S; Nicolini, F; Ponzoni, M; Rotiroti, MC; Scarfò, L; Tettamanti, S; Veliz Rodriguez, T; Wierda, W; Zhang, R | 1 |
| Chen, PH; Ho, CL; Lee, CH; Lin, C; Wang, CY | 1 |
| Bellido, M; Chamuleau, MED; de Boer, F; Dobber, JA; Doorduijn, JK; Hoogendoorn, M; Kater, AP; Kerst, JM; Kersting, SS; Koene, HR; Langerak, AW; Levin, MD; Marijt, EWA; Posthuma, WFM; Raymakers, RAP; Saberi Hosnijeh, F; Schaafsma, MR; Te Raa, GD; Tonino, SH; van der Straten, L; van Gelder, M; van Oers, MHJ | 1 |
| Andritsos, LA; Awan, FT; Badawi, M; Byrd, JC; Bystry, DM; Epperla, N; Jones, J; Mo, X; Phelps, MA; Rike, L; Rogers, KA; Thangavadivel, S; Woyach, JA; Zhao, Q | 1 |
| Bickerstaff, M; Bloor, A; Carruthers, S; Cicconi, S; Coupland, SE; Dearden, C; Dodd, J; Duncombe, A; Fegan, C; Fox, CP; Hillmen, P; Jackson, R; Kalakonda, N; Kennedy, B; Khan, UT; Lin, K; Marshall, S; McCarthy, H; Menon, G; Oates, M; Pettitt, AR; Polydoros, F; Schuh, A; Stackpoole, M; Walewska, R; Yap, C | 1 |
| Abreu, MM; Gouvea, J; Jewett, A; Ko, MW; Maharaj, D; Srinivasan, G | 1 |
| Böttcher, S; Brüggemann, M; Coscia, M; Crespo, M; de la Serna, J; Eckert, R; Eichhorst, B; Fink, AM; Fischer, K; Fürstenau, M; Hallek, M; Herling, CD; Ritgen, M; Robrecht, S; Schilhabel, A; Stilgenbauer, S; Tausch, E; Vitale, C; Weiss, J; Weppner, G | 1 |
| Jain, A; Jindal, N; Khadwal, A; Lad, DP; Malhotra, P; Naseem, S; Prakash, G; Sachdeva, MS; Sreedharanunni, S; Varma, N; Varma, S | 1 |
| Atene, CG; Benatti, S; Fiorcari, S; Luppi, M; Maffei, R; Marasca, R; Martinelli, S; Potenza, L; Zucchini, P | 1 |
| Barna, G; Czeti, Á; Hernádfői, M; Kriston, C; Márk, Á; Matolcsy, A; Plander, M; Szabó, O; Szalóki, G; Takács, F | 1 |
| Brown, JR; Itchaki, G | 1 |
| Ahmed, S; Alousi, AM; Bassett, RL; Bueso-Ramos, CE; Ciurea, SO; Gulbis, AM; Jabbour, EJ; Khouri, IF; Khouri, MR; Korbling, M; Ledesma, C; Marin, D; Patel, KK; Popat, UR; Samuels, BI; Turturro, F | 1 |
| Benatti, S; Bulgarelli, J; Cuneo, A; Debbia, G; Fiorcari, S; Forconi, F; Gaidano, G; Laurenti, L; Luppi, M; Maffei, R; Marasca, R; Martinelli, S; Palumbo, GA; Rigolin, GM; Rizzotto, L; Rossi, D; Santachiara, R; Vallisa, D | 1 |
| Burger, JA; Estrov, Z; Ferrajoli, A; Keating, MJ; O'Brien, SM; Strati, P; Wierda, WG; Zacharian, G | 1 |
| Al-Sawaf, O; Aldaoud, A; Bahlo, J; Bosch, F; Böttcher, S; Döhner, H; Dörfel, S; Eichhorst, B; Fink, AM; Fischer, K; Ghia, P; Hallek, M; Hebart, H; Jentsch-Ullrich, K; Kater, AP; Kneba, M; Kreuzer, KA; Nösslinger, T; Ritgen, M; Robrecht, S; Stilgenbauer, S; Tausch, E; Wendtner, CM | 1 |
| Condoluci, A; Rossi, D | 1 |
| Chanan-Khan, AA; Egyed, M; Foà, R; Kassis, J; Purse, B; Schuh, A; Semochkin, S; Simpson, D; Vokurka, S; Zaritskey, A; Zhang, J | 1 |
| Clifton-Hadley, L; Counsell, N; Cwynarski, K; Gohil, SH; Maciocia, N; Nathwani, AC; Patrick, P; Pettitt, A; Roberts, T; Smith, P | 1 |
| Burger, JA; Estrov, Z; Ferrajoli, A; Hinojosa, CO; Jain, N; Kantarjian, HM; Keating, MJ; O'Brien, SM; Rezvani, K; Strati, P; Thompson, PA; Wierda, WG | 1 |
| Orna, E; Sancho, JM; Sorigue, M | 1 |
| Adamson, L; Eriksson, I; Gentilcore, G; Hansson, L; Heimersson, K; Mellstedt, H; Mozaffari, F; Mulder, TA; Näsman-Glaser, B; Österborg, A; Palma, M; Ryblom, H; Svensson, A | 1 |
| Cheson, BD; Khan, N; Ramzi, P; Skarbnik, A; Trivedi, N; Ujjani, C; Wang, H | 1 |
| Bai, H; Fan, WJ; Fan, ZQ; Wu, T | 1 |
| Foà, R; Mauro, FR | 1 |
| Catakovic, K; Egle, A; Gassner, FJ; Geisberger, R; Girschikofsky, M; Greil, R; Hartmann, TN; Lang, A; Melchardt, T; Petzer, A; Pleyer, L; Steurer, M; Thaler, J; Voskova, D; Weiss, L; Zaborsky, N | 1 |
| Appelbaum, FR; Byrd, JC; Chang, JE; Couban, S; Fehniger, TA; Godwin, JE; Halvorson, AE; Heerema, NA; Hoke, E; Larson, RA; Mandrekar, SJ; Robinson, S; Ruppert, AS; Smith, MR; Stone, RM; Tallman, MS; Thirman, MJ | 1 |
| Aue, G; Lee, E; Liu, D; Maric, I; Muranski, P; Nakamura, Y; Park, JH; Pittaluga, S; Soto, S; Stetler-Stevenson, M; Sun, C; Tian, X; Valdez, J; Wiestner, A; Yuan, C | 1 |
| Chen, CI; Croucher, D; Gibson, SB; Johnston, JB; Kakar, S; Lau, A; Le, LW; Paul, H; Queau, M; Sherry, B; Snitzler, S; Spaner, D; Trudel, S; Wei, EN | 1 |
| Ferrajoli, A; Vitale, C | 1 |
| Gonzalez, S; Gonzalez-Garcia, E; Gonzalez-Rodriguez, AP; López-Soto, A; Lorenzo-Herrero, S; Payer, AR; Sordo-Bahamonde, C; Villa-Álvarez, M; Villa-Álvarez, MC | 1 |
| Blum, KA; Blum, W; Byrd, JC; Foster, DJR; Gao, Y; Grever, MR; Hofmeister, CC; Hughes, JH; Marcucci, G; Phelps, MA; Reuter, SE; Upton, RN | 1 |
| Abramson, JS; Amrein, PC; Armand, P; Brown, JR; Davids, MS; Fisher, DC; Hochberg, EP; Neuberg, D; Soumerai, JD; Werner, L | 1 |
| Abramson, JS; Advani, RH; Andreadis, CB; Bartlett, N; Bellam, N; Byrd, JC; Czuczman, MS; Dwyer, MA; Fayad, LE; Glenn, MJ; Gockerman, JP; Gordon, LI; Harris, NL; Hoppe, RT; Horwitz, SM; Kelsey, CR; Kim, YH; Krivacic, S; LaCasce, AS; Nademanee, A; Naganuma, M; Porcu, P; Press, O; Pro, B; Reddy, N; Sokol, L; Swinnen, L; Tsien, C; Vose, JM; Wierda, WG; Yahalom, J; Zafar, N; Zelenetz, AD | 1 |
| Bowen, D; Call, TG; Hanson, CA; Jelinek, DF; Kay, NE; LaPlant, B; Leis, JF; Pettinger, A; Ramsay, AG; Shanafelt, TD; Tun, HW; Zent, CS | 1 |
| Ysebaert, L | 1 |
| Akinleye, A; Wu, M; Zhu, X | 1 |
| Johnston, JB | 1 |
| Cutucache, CE | 1 |
| Badoux, XC; Calin, S; Ferrajoli, A; Gao, H; Kantarjian, HM; Keating, MJ; Kornblau, SM; O'Brien, S; Reuben, JM; Strati, P; Wierda, WG | 1 |
| Gilbert, JA | 1 |
| Wendtner, CM | 2 |
| Fan, L; Han, TT; Li, JY; Xu, W | 1 |
| Cooper, LJ; Kharfan-Dabaja, MA; Wierda, WG | 1 |
| Acebes-Huerta, A; Gonzalez, S; Gonzalez-García, E; González-Rodríguez, AP; Huergo-Zapico, L; Payer, AR; Villa-Alvarez, M | 1 |
| Bonacorsi, G; Bulgarelli, J; Castelli, I; Cuneo, A; Debbia, G; Fiorcari, S; Forconi, F; Gaidano, G; Laurenti, L; Luppi, M; Maffei, R; Marasca, R; Martinelli, S; Palumbo, GA; Rigolin, GM; Rizzotto, L; Rossi, D; Santachiara, R; Vallisa, D | 1 |
| Alousi, A; Di Stasi, A; Hosing, C; Keating, M; Mehta, RS; O'Brien, S; Rezvani, K; Shah, N; Shpall, EJ; Wierda, W | 1 |
| Baumann, T; Delgado, J; Montserrat, E; Santacruz, R | 1 |
| Catakovic, K; Egle, A; Gassner, FJ; Geisberger, R; Greil, R; Hartmann, TN; Huemer, M; Melchardt, T; Neureiter, D; Rebhandl, S; Zaborsky, N | 1 |
| Bergsagel, PL; Chen, CI; Dave, N; Kukreti, V; Lau, A; Le, LW; Nong Wei, E; Paul, H; Trudel, S; Wang, T | 1 |
| Lei, W; Li, YF; Zhou, KS | 1 |
| Burger, J; Faderl, S; Ferrajoli, A; Jain, N; Keating, MJ; O'Brien, SM; Strati, P; Tambaro, FP; Wierda, WG | 1 |
| Barrientos, JC; Brown, JR; Castro, JE; Greaves, A; James, DF; Johnson, AJ; Kipps, TJ; Neuberg, D; Rai, KR; Rassenti, LZ; Werner, L; Wierda, WG | 1 |
| Bharati, IS; Cathers, B; Corral, LG; Cui, B; Fecteau, JF; Futalan, D; Gaidarova, S; Ghia, EM; Kipps, TJ; Lopez-Girona, A; Messmer, D; Schwaederlé, M | 1 |
| Gribben, JG; Riches, JC | 2 |
| Andritsos, LA; Browning, R; Byrd, JC; Flynn, J; Gao, Y; Harper, E; Jiang, Y; Johnson, AJ; Jones, J; Kefauver, C; Maddocks, K; Phelps, MA; Poi, M; Rozewski, DM; Ruppert, AS | 1 |
| Afrin, LB; Bentz, TA; Costa, LJ; Fanning, SR; Kistner-Griffin, E; Stephenson, J; Stuart, RK | 1 |
| Egle, A; Kater, AP; Ramsay, AG; Tonino, SH | 1 |
| Seiffert, M | 1 |
| Andreadis, C; Gupta, NK | 1 |
| Acebes-Huerta, A; Fernandez-Guizan, A; Gonzalez, S; Gonzalez-Rodriguez, AP; Huergo-Zapico, L; López-Soto, A; Payer, AR | 1 |
| Audrito, V; Bulgarelli, J; Colaci, E; Deaglio, S; Fiorcari, S; Luppi, M; Maffei, R; Marasca, R; Martinelli, S; Narni, F; Potenza, L; Zucchini, P | 1 |
| Abdul-Hay, M; Desai, AV; El-Bakkar, H | 1 |
| Caivano, A; D'Arena, G; D'Auria, F; Del Vecchio, L; La Rocca, F; Musto, P; Ruggieri, V; Simeon, V; Statuto, T; Telesca, D | 1 |
| Adusumilli, M; Andritsos, LA; Blum, KA; Byrd, JC; Cardone, MH; Doykin, C; Flynn, J; Grever, MR; Jiang, Y; Johnson, AJ; Jones, JA; Maddocks, K; Phelps, MA; Pierceall, WE; Rozewski, D; Wei, L; Zhao, Y | 1 |
| Sun, C; Wiestner, A | 1 |
| Azzollini, K; Bejot, C; Bhattacharyya, PK; Chow, KF; Feldman, T; Foon, KA; Gadaleta, G; Goy, A; Howlett, C; Kdiry, S; Mato, AR; Mrkulic, M; Pascual, LN; Porter, D; Schuster, SJ; Strelec, L; Svoboda, J; Valentinetti, M; Yannotti, K; Zenreich, J | 1 |
| Rosen, ST; Siddiqi, T | 1 |
| Colaci, E; Fiorcari, S; Luppi, M; Maffei, R; Marasca, R; Martinelli, S; Potenza, L | 1 |
| Bahlo, J; Bergmann, M; Binder, M; Böttcher, S; Cramer, P; Döhner, H; Dreyling, M; Eichhorst, B; Fink, AM; Fischer, K; Fischer, N; Gross-Ophoff, C; Hallek, M; Kluth, S; Kneba, M; Kreuzer, KA; Langerbeins, P; Maurer, C; Pflug, N; Rhein, C; Stilgenbauer, S; Tausch, E; Wendtner, CM | 1 |
| Burger, JA; Calin, G; Faderl, S; Falchi, L; Ferrajoli, A; Gao, H; Keating, MJ; O'Brien, S; Reuben, JM; Rezvani, K; Shaim, H; Ten Hacken, E; Van Roosbroeck, K; Vitale, C; Wang, X; Wierda, WG | 1 |
| Buhler, A; Chanan-Khan, A; De Bedout, S; Dürig, J; Fraser, GA; Gribben, JG; Hallek, M; Hillmen, P; Kalaycio, M; Kipps, TJ; Mei, J; Michallet, AS; Purse, B; Stilgenbauer, S; Wendtner, CM; Zhang, J | 1 |
| Blank, J; Chang, JE; Eickhoff, J; Go, RS; Havighurst, T; Kahl, BS; Kim, K; Kirby-Slimp, R; Traynor, AM; Volk, LM; Weiss, M; Werndli, J | 1 |
| Aurran-Schleinitz, T; Bühler, A; Chanan-Khan, A; De Bedout, S; Dürig, J; Fraser, GA; Gregory, SA; Gribben, JG; Hallek, M; Hillmen, P; Kalaycio, M; Kipps, TJ; Mei, J; Michallet, AS; Purse, B; Rassenti, L; Stilgenbauer, S; Trentin, L; Wendtner, CM; Zhang, J | 1 |
| Chavez, JC; Dalia, S; Kharfan-Dabaja, MA; Komrokji, R; Lancet, J; Locke, FL; Nodzon, L; Pinilla-Ibarz, J; Piris-Villaespesa, M; Powers, J; Sokol, L; Sotomayor, EM; Turba, E | 1 |
| Browning, RL; Byrd, JC; Byrd, WH; Gupta, N; Hertlein, E; Jones, J; Mo, X; Muthusamy, N; Yu, L | 1 |
| Hu, X; Liang, L; Liu, H; Yang, LP; Zhao, M; Zhu, YC | 1 |
| Belsito, V; Carella, AM; Cortellezzi, A; Cuneo, A; De Propris, MS; Ferretti, A; Foà, R; Guarini, AR; Liberati, AM; Marinelli, M; Mauro, FR; Molica, S; Nanni, M; Orlando, SM; Paoloni, F; Rizzi, R; Spriano, M; Tosi, P; Vignetti, M; Zaja, F | 1 |
| Blonski, JZ; Chanan-Khan, A; Desjardins, P; Dolan, S; Echeveste, MA; Egyed, M; Golany, N; Gribben, JG; Martinelli de Oliveira, FA; Mei, J; Robak, T; Zhang, J | 1 |
| Blum, W; Byrd, JC; Gorgün, G; Gribben, JG; Johnson, AJ; Le Dieu, R; Lee, AM; Ramsay, AG | 1 |
| Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A | 1 |
| Schiffer, CA; Srinivasan, S | 1 |
| Andritsos, L; Blum, W; Butchar, JP; Byrd, JC; Chen, CS; Johnson, AJ; Lapalombella, R; Lee, LJ; Lee, RJ; Lehman, A; Liu, Q; Lozanski, G; Marcucci, G; Muthusamy, N; Ramanunni, A; Smith, LL; Triantafillou, G; Tridandapani, S; Wang, DS; Yu, B | 1 |
| Bangia, N; Chanan-Khan, AA; Lee, K; Porter, CW; Whitworth, A | 1 |
| Lin, TS | 2 |
| Wiernik, PH | 2 |
| Fricker, J | 1 |
| Byrd, JC; Caligiuri, MA; Chen, CS; Cheney, C; Gowda, A; Johnson, AJ; Joshi, T; Lapalombella, R; Lehman, A; Mehter, N; Muthusamy, N; Tridandapani, S | 1 |
| Croce, CM; Gorgun, G; Gribben, JG; Holderried, TA; Le Dieu, R; Liu, F; Quackenbush, J; Ramsay, AG; Zahrieh, D | 1 |
| Aue, G; Boss, C; Gibellini, F; Hughes, T; Keyvanfar, K; McCoy, JP; Njuguna, N; Pittaluga, S; Samsel, L; Soto, S; Tian, X; Valdez, J; Vire, B; Wiestner, A; Wilson, WH | 1 |
| Bhattacharya, N; Döhner, H; Giannopoulos, K; Idler, I; Mertens, D; Nothing, M; Stilgenbauer, S; Zenz, T | 1 |
| Andritsos, L; Blum, KA; Blum, W; Browning, R; Byrd, JC; Chen, CS; Ford, R; Jarjoura, D; Johnson, AJ; Lapalombella, R; Lehman, A; Liu, Q; May, SE; Mo, X; Muthusamy, N; Pham, LV; Rader, C; Ramanunni, A; Raymond, CA; Smith, LL | 1 |
| Bazargan, A; Tam, CS | 1 |
| Awan, FT; Byrd, JC; Fischer, B; Hu, W; Johnson, AJ; Lapalombella, R; Lucas, M | 1 |
| Bilgrami, SA; Block, AW; Chanan-Khan, AA; Czuczman, MS; Hernandez-Ilizaliturri, F; Lawrence, D; Lawrence, W; Lee, K; Miller, A; Miller, KC; Sher, T; Sood, R; Whitworth, A; Wood, MT | 1 |
| Brown, JR | 1 |
| Chanan-Khan, A; Miller, KC; Musial, L; Whitworth, A | 1 |
| Bergsagel, PL; Brandwein, J; Chen, CI; Dave, N; Gibson, S; Hernandez, T; Johnston, J; Kukreti, V; Lau, A; Leung-Hagesteijn, C; Li, ZH; Pantoja, M; Paul, H; Spaner, D; Trudel, S; Wei, E; Xu, W | 1 |
| Bisconte, MG; Bossio, S; Caruso, N; De Stefano, L; Franzese, S; Gentile, C; Gentile, M; Gigliotti, V; Lucia, E; Madeo, A; Mazzone, C; Morabito, F; Morabito, L; Recchia, AG; Servillo, P; Vigna, E | 1 |
| Kay, NE; O'Brien, S | 1 |
| Abou-Nassar, K; Brown, JR | 1 |
| Blum, KA; Byrd, JC; Gordon, AL; Herman, SE; Johnson, AJ; Jones, J; Lannutti, BJ; Lapalombella, R; Muthusamy, N; Puri, KD; Ramanunni, A; Zhang, X | 1 |
| Giorgadze, T; Tageja, N; Zonder, J | 1 |
| Chanan-Khan, A; Czuczman, MS; Hernandez-Illatazurri, F; Lawrence, D; Lee, K; Miller, A; Miller, KC; Padmanabhan, S; Wallace, PK; Zeldis, JB | 1 |
| Arumainathan, A; Kalakonda, N; Pettitt, AR | 1 |
| Buckstein, R; Czuczman, MS; Ervin-Haynes, A; Li, J; Pietronigro, D; Polikoff, J; Reeder, CB; Vose, JM; Witzig, TE; Zinzani, PL | 1 |
| Badoux, XC; Burger, JA; Faderl, S; Ferrajoli, A; Keating, MJ; Kornblau, SM; Lee, BN; O'Brien, SM; Reuben, J; Sivina, M; Wen, S; Wierda, WG | 1 |
| Aue, G; Cullinane, AM; McCoy, P; Nelson Lozier, J; Samsel, L; Soto, S; Tian, X; Wiestner, A | 1 |
| Badoux, X; Cohen, EN; Estrov, Z; Faderl, SH; Ferrajoli, A; Gao, H; Keating, MJ; Lee, BN; Reuben, JM; Wierda, WG | 1 |
| Bloor, A; Bosch, F; Bühler, A; Chanan-Khan, AA; Coutré, S; Dreisbach, L; Ferrajoli, A; Frankfurt, O; Furman, RR; Gobbi, M; Gribben, JG; Hallek, M; Heerema, NA; Hillmen, P; Hurd, DD; Kimby, E; Mahadevan, D; Moutouh-de Parseval, L; Sekeres, MA; Shah, S; Stilgenbauer, S; Uharek, L; Wendtner, CM; Zhang, J | 1 |
| Bangia, N; Borrello, I; Chanan-Khan, AA; Chitta, K; Czuczman, MS; Ersing, N; Lee, K; Mashtare, TL; Masood, A; Paulus, A; Sher, T; Swaika, A; Wallace, PK; Wilding, G | 1 |
| Giannopoulos, K; Mertens, D; Stilgenbauer, S | 1 |
| Ailawadhi, S; Borrelo, I; Chanan-Khan, A; Chitta, K; Ersing, N; Khan, AN; Lee, KP; Manfredi, D; Masood, A; Miller, KC; Paulus, A; Sher, T | 1 |
| Gribben, JG; Ramsay, AG; Riches, JC | 1 |
| Clear, AJ; Fatah, R; Gribben, JG; Ramsay, AG | 1 |
| Lentzsch, S; Pan, B | 1 |
| Hansson, L; Karlsson, C; Lundin, J; Mozaffari, F; Norin, S; Österborg, A; Porwit, A; Rossmann, E; Sylvan, SE | 1 |
| Chen, CI | 1 |
| Badoux, XC; Burger, JA; Faderl, S; Ferrajoli, A; Keating, MJ; O'Brien, SM; Sargent, R; Wen, S; Wierda, WG | 1 |
| Corradini, P; Farina, L; Rezzonico, F; Spina, F | 1 |
| Evans, R; Gribben, JG; Hogg, N; Kiaii, S; Ramsay, AG; Svensson, L | 1 |
| Döhner, H; Dürr, C; Lichter, P; Schulz, A; Seiffert, M; Stilgenbauer, S; Zenz, T | 1 |
| Gibson, AD; Klem, J; Price, N; Reddy, GK | 1 |
| Chanan-Khan, A; Porter, CW | 1 |
| Bernstein, ZP; Byrne, C; Chanan-Khan, A; Chrystal, C; Czuczman, MS; Goodrich, DW; Hernandez-Ilizaliturri, F; Lawrence, D; Miller, KC; Mohr, A; Musial, L; Padmanabhan, S; Porter, CW; Spaner, D; Starostik, P; Takeshita, K; Wallace, P | 1 |
| Molica, S | 1 |
| Snively, A | 1 |
| DeLap, RJ; Knight, RD; Moutouh-de Parseval, LA; Weiss, L; Zeldis, JB | 1 |
| Czuczman, MS; Deeb, G; Hernandez-Ilizaliturri, FJ; Knight, J; Reddy, N; Roth, M; Vaughn, M; Wallace, P | 1 |
| Chanan-Khan, AA; Cheson, BD | 1 |
| Cohen, EN; Estrov, Z; Faderl, S; Ferrajoli, A; Gao, H; Keating, MJ; Lee, BN; Li, C; O'Brien, SM; Reuben, JM; Schlette, EJ; Wen, S; Wierda, WG | 1 |
| Andritsos, LA; Awan, F; Blum, W; Byrd, JC; Chen, CS; Jarjoura, D; Johnson, AJ; Kefauver, C; Knight, RD; Lapalombella, R; Lehman, A; Lozanski, G; May, SE; Raymond, CA; Ruppert, AS; Smith, LL; Wang, DS | 1 |
| Awais, A; Cortes, J; Duvic, M; Ferrajoli, A; Keating, MJ; Kontoyiannis, D; Tam, CS | 1 |
38 review(s) available for lenalidomide and Leukemia, Lymphocytic, Chronic, B-Cell
| Article | Year |
|---|---|
A network meta-analysis of maintenance therapy in chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Maintenance Chemotherapy; Network Meta-Analysis; Randomized Controlled Trials as Topic; Rituximab; Survival Analysis; Treatment Outcome | 2020 |
Lenalidomide in the treatment of chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Recurrence; Thalidomide | 2017 |
Venous thromboembolism in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with lenalidomide: a systematic review.
Topics: Angiogenesis Inhibitors; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Meta-Analysis as Topic; Prognosis; Prospective Studies; Venous Thromboembolism | 2018 |
[Research and Applications Progress of Lenalidomide in Relapsed / Refractory Blood System Diseases -Review].
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Multiple Myeloma; Thalidomide | 2018 |
Novel agents for chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Nitrogen Mustard Compounds; Thalidomide | 2013 |
Tumor-induced host immunosuppression: special focus on CLL.
Topics: Antineoplastic Agents; Gene Expression Regulation; HLA-G Antigens; Humans; Immunosuppression Therapy; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Thalidomide | 2013 |
[Chemotherapy-free treatment of chronic lymphocytic leukemia?].
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Clinical Trials as Topic; Drugs, Investigational; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Rituximab; Thalidomide | 2013 |
Role of chemokines and their receptors in chronic lymphocytic leukemia: function in microenvironment and targeted therapy.
Topics: Aminopyridines; Antineoplastic Agents; Benzylamines; Chemokine CXCL12; Clinical Trials as Topic; Cyclams; Dasatinib; Heterocyclic Compounds; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Morpholines; Niacinamide; Oxazines; Phenylurea Compounds; Protein Kinase Inhibitors; Purines; Pyridines; Pyrimidines; Quinazolinones; Receptors, CXCR4; Sorafenib; Thalidomide; Thiazoles; Tumor Microenvironment | 2014 |
Immunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitors.
Topics: Agammaglobulinaemia Tyrosine Kinase; Cell Transplantation; Hematopoietic Stem Cell Transplantation; Humans; Immune Tolerance; Immunotherapy; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Thalidomide | 2014 |
Lenalidomide and chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Immunologic Factors; Immunomodulation; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Thalidomide | 2013 |
New treatment options for chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Humans; Immunotherapy; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Recurrence, Local; Receptors, Antigen, B-Cell; Signal Transduction; Thalidomide | 2014 |
[Application of lenalidomide in chronic lymphocytic leukemia].
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Thalidomide | 2014 |
Immunomodulation and immune reconstitution in chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal; Cancer Vaccines; CD40 Ligand; Humans; Immunologic Factors; Immunotherapy; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; T-Lymphocytes; Thalidomide | 2014 |
How does lenalidomide target the chronic lymphocytic leukemia microenvironment?
Topics: B-Lymphocytes; Biomarkers, Tumor; Clinical Trials as Topic; Gene Expression Regulation, Neoplastic; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Purines; Quinazolinones; T-Lymphocytes; Thalidomide | 2014 |
New meets old: a case study and review of novel therapeutics for the treatment of CLL in older patients.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Radionuclide Imaging; Rituximab; Thalidomide; Treatment Outcome | 2014 |
Novel agents in the treatment of chronic lymphocytic leukemia: a review about the future.
Topics: Adenine; Aniline Compounds; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cyclic N-Oxides; Flavonoids; Humans; Immunologic Factors; Indolizines; Isoquinolines; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Purines; Pyrazoles; Pyridinium Compounds; Pyrimidines; Quinazolinones; Receptors, Antigen, T-Cell; Sulfonamides; Thalidomide | 2015 |
Prognosis and therapy of chronic lymphocytic leukemia and small lymphocytic lymphoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Biomarkers, Tumor; Chromosome Deletion; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 17; Humans; Integrin alpha4; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Precision Medicine; Prognosis; Protein Kinase Inhibitors; Smith-Magenis Syndrome; Thalidomide; ZAP-70 Protein-Tyrosine Kinase | 2015 |
Novel biologic agents for non-Hodgkin lymphoma and chronic lymphocytic leukemia-part 2: adoptive cellular immunotherapy, small-molecule inhibitors, and immunomodulation.
Topics: Aniline Compounds; Antineoplastic Agents; Clinical Trials as Topic; Humans; Immunomodulation; Immunotherapy, Adoptive; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Prognosis; Protein-Tyrosine Kinases; Purines; Quinazolinones; Randomized Controlled Trials as Topic; Recurrence; Sulfonamides; Thalidomide; Treatment Outcome | 2015 |
Lenalidomide in chronic lymphocytic leukemia: the present and future in the era of tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Protein Kinase Inhibitors; Thalidomide | 2016 |
Mechanistic and Clinical Aspects of Lenalidomide Treatment for Chronic Lymphocytic Leukemia.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Cell Proliferation; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Protein Kinase Inhibitors; Receptors, Antigen, B-Cell; Thalidomide | 2016 |
Efficacy of lenalidomide in relapsed/refractory chronic lymphocytic leukemia patient: a systematic review and meta-analysis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Outcome Assessment, Health Care; Recurrence; Rituximab; Thalidomide | 2016 |
[Novel medical treatment modalities in hematology].
Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Benzoates; Boronic Acids; Bortezomib; Carbazoles; Carrier Proteins; Cyclophosphamide; Dasatinib; Furans; Gemtuzumab; Hematologic Diseases; Humans; Hydrazines; Imatinib Mesylate; Immunologic Factors; Indoles; Lenalidomide; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Piperazines; Purpura, Thrombocytopenic; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thalidomide; Thiazoles; Thrombopoietin; Vidarabine | 2008 |
Novel agents in chronic lymphocytic leukemia: efficacy and tolerability of new therapies.
Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Flavonoids; Humans; Indoles; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Maximum Tolerated Dose; Nitrogen Mustard Compounds; Piperidines; Pyrroles; Thalidomide; Thionucleotides; Treatment Outcome | 2008 |
Treatment of hematologic neoplasms with new immunomodulatory drugs (IMiDs).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Combined Modality Therapy; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Salvage Therapy; Thalidomide; Venous Thromboembolism; Young Adult | 2009 |
Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor; Clinical Trials as Topic; Humans; Killer Cells, Natural; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Medical Oncology; T-Lymphocytes; Thalidomide; Treatment Outcome | 2010 |
New agents in chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Delivery Systems; Drugs, Investigational; Flavonoids; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Proteins; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Thalidomide | 2010 |
Management of patients with chronic lymphocytic leukemia treated with lenalidomide.
Topics: Antineoplastic Agents; Drug Administration Schedule; Drug Monitoring; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Thalidomide | 2010 |
Lenalidomide in the treatment of chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Combined Modality Therapy; Humans; Immune System Diseases; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Thalidomide; Tumor Microenvironment | 2011 |
Maintenance therapy for B-chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal, Murine-Derived; Catechin; Curcumin; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Thalidomide | 2011 |
Novel agents for the treatment of chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Humans; Immunoglobulin G; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Recombinant Fusion Proteins; Thalidomide | 2010 |
Treating chronic lymphocytic leukemia with thalidomide and lenalidomide.
Topics: Adjuvants, Immunologic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Thalidomide; Treatment Outcome | 2011 |
Immune reconstitution in chronic lymphocytic leukemia.
Topics: Adoptive Transfer; Antineoplastic Agents; CD40 Ligand; Genetic Therapy; Humans; Immunotherapy; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; T-Lymphocytes; Thalidomide | 2012 |
The application and biology of immunomodulatory drugs (IMiDs) in cancer.
Topics: Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms; Neoplasms, Second Primary; Thalidomide | 2012 |
Lenalidomide alone and in combination for chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Thalidomide | 2013 |
Lenalidomide in lymphomas and chronic lymphocytic leukemia.
Topics: Angiogenesis Inhibitors; Clinical Trials as Topic; Disease-Free Survival; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Thalidomide | 2013 |
Immunomodulating drugs for chronic lymphocytic leukaemia.
Topics: Aged; Antineoplastic Agents; Clinical Trials as Topic; Combined Modality Therapy; Cytokines; Down-Regulation; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Middle Aged; Thalidomide | 2006 |
Immunomodulatory drugs in chronic lymphocytic leukemia: a new treatment paradigm.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Remission Induction; Thalidomide; Treatment Outcome | 2007 |
Lenalidomide for the treatment of B-cell malignancies.
Topics: Amyloidosis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytokines; Gene Expression Regulation, Neoplastic; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Multicenter Studies as Topic; Multiple Myeloma; Randomized Controlled Trials as Topic; Thalidomide; Waldenstrom Macroglobulinemia | 2008 |
47 trial(s) available for lenalidomide and Leukemia, Lymphocytic, Chronic, B-Cell
| Article | Year |
|---|---|
Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Chlorambucil; Disease-Free Survival; Female; Gene Expression; Humans; Immunoglobulin Heavy Chains; Immunotherapy; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Prognosis; Proteinase Inhibitory Proteins, Secretory; Proteomics; Receptors, IgE; Rituximab; Signaling Lymphocytic Activation Molecule Family; Treatment Outcome; Tumor Necrosis Factor Receptor Superfamily, Member 7 | 2020 |
Early Intervention with Lenalidomide in Patients with High-risk Chronic Lymphocytic Leukemia.
Topics: Adult; Aged; Angiogenesis Inhibitors; Female; Follow-Up Studies; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Survival Rate | 2020 |
B-cell acute lymphoblastic leukemia in patients with chronic lymphocytic leukemia treated with lenalidomide.
Topics: B-Lymphocytes; Female; Humans; Immunologic Factors; Incidence; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Risk Factors | 2021 |
Randomized controlled trial of individualized, low dose, fixed duration lenalidomide maintenance versus observation after frontline chemo-immunotherapy in CLL.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Immunotherapy; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Quality of Life; Treatment Outcome | 2021 |
Feasibility of Lenalidomide Therapy for Persistent Chronic Lymphocytic Leukemia after Allogeneic Transplantation.
Topics: Acute Disease; Aged; Allografts; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Transfusion; Male; Middle Aged; Stem Cell Transplantation; Survival Rate; Thalidomide | 2017 |
Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Cytokines; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Immunomodulation; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Subsets; Monocytes; Thalidomide | 2018 |
Consolidation treatment with lenalidomide following front-line or salvage chemoimmunotherapy in chronic lymphocytic leukemia.
Topics: Adult; Aged; Consolidation Chemotherapy; Female; Humans; Immunotherapy; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged | 2017 |
Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm, Residual; Survival Analysis; Thalidomide; Treatment Outcome | 2017 |
Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Thalidomide; Treatment Outcome | 2017 |
Lenalidomide as immune adjuvant to a dendritic cell vaccine in chronic lymphocytic leukemia patients.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Apoptosis; Cancer Vaccines; Combined Modality Therapy; Cyclophosphamide; Cytokines; Cytotoxicity, Immunologic; Dendritic Cells; Disease Progression; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Injections, Intravenous; Injections, Subcutaneous; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Thalidomide; Thrombocytopenia; Transplantation, Autologous; Tumor Cells, Cultured; Vaccination | 2018 |
A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL.
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Piperidines; Progression-Free Survival; Pyrazoles; Pyrimidines; Recurrence; Remission Induction; Rituximab; Salvage Therapy | 2018 |
Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CD4-Positive T-Lymphocytes; Consolidation Chemotherapy; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; Female; Hematologic Diseases; Humans; Immunity, Cellular; Immunologic Memory; Immunotherapy; Kaplan-Meier Estimate; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Maintenance Chemotherapy; Male; Maximum Tolerated Dose; Middle Aged; Remission Induction; Rituximab; T-Lymphocyte Subsets; Thalidomide; Treatment Outcome; Vidarabine | 2018 |
Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance).
Topics: Adult; Aged; Aged, 80 and over; Consolidation Chemotherapy; Disease-Free Survival; Female; Humans; Immunotherapy; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Survival Rate | 2018 |
Activation of Th1 Immunity within the Tumor Microenvironment Is Associated with Clinical Response to Lenalidomide in Chronic Lymphocytic Leukemia.
Topics: Antineoplastic Agents; Cell Differentiation; Cell Proliferation; Cells, Cultured; Cytokines; Gene Expression Profiling; Humans; Immunization; Interferon-gamma; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Activation; Receptors, Antigen, T-Cell; Receptors, Antigen, T-Cell, alpha-beta; Th1 Cells; Treatment Outcome; Tumor Microenvironment | 2018 |
A phase 2 study of lenalidomide and dexamethasone in previously untreated patients with chronic lymphocytic leukemia (CLL).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cytokines; Dexamethasone; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Prognosis; Treatment Outcome | 2019 |
Phase 1 study of lenalidomide, bendamustine, and rituximab in previously untreated patients with chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Drug Administration Schedule; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Prognosis; Remission Induction; Rituximab; Treatment Outcome | 2019 |
Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL).
Topics: Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Combined Modality Therapy; Consolidation Chemotherapy; Humans; Immunological Synapses; Immunotherapy; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Neoadjuvant Therapy; Recovery of Function; Retrospective Studies; T-Lymphocytes; Thalidomide; Time Factors; Treatment Outcome | 2013 |
Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Disease-Free Survival; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Male; Neoplasm, Residual; Remission Induction; T-Lymphocytes; Thalidomide; Time Factors | 2013 |
Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia.
Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Cell Survival; Endothelial Cells; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Thalidomide | 2014 |
Long-term follow-up of a phase 2 trial of single agent lenalidomide in previously untreated patients with chronic lymphocytic leukaemia.
Topics: Adult; Aged; Angiogenesis Inhibitors; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Thalidomide; Treatment Outcome | 2014 |
A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Cohort Studies; Dose-Response Relationship, Drug; Feasibility Studies; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Maximum Tolerated Dose; Middle Aged; Recurrence; Thalidomide; Treatment Outcome | 2014 |
Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Thalidomide; Thrombocytopenia; Treatment Outcome | 2015 |
Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Flavonoids; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Maximum Tolerated Dose; Middle Aged; Piperidines; Recurrence; Thalidomide; Treatment Outcome; Tumor Lysis Syndrome | 2015 |
Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Remission Induction; Rituximab; Survival Rate; Thalidomide; Vidarabine | 2015 |
Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chromosome Aberrations; Drug Administration Schedule; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Rituximab; Thalidomide; Treatment Outcome | 2016 |
Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Disease-Free Survival; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Thalidomide; Treatment Outcome | 2016 |
Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Humans; Immunologic Factors; Kaplan-Meier Estimate; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Recurrence; Retreatment; Thalidomide; Treatment Outcome | 2016 |
Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease Progression; Disease-Free Survival; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Recurrence; Remission Induction; Rituximab; Thalidomide; Treatment Outcome | 2016 |
Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Immunoglobulin Heavy Chains; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Prognosis; Recurrence; Retreatment; Survival Analysis; Thalidomide; Treatment Outcome; Tumor Suppressor Protein p53 | 2016 |
Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans; Infections; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Remission Induction; Rituximab; Salvage Therapy; Thalidomide | 2016 |
Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I-II GIMEMA trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cyclophosphamide; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Maximum Tolerated Dose; Middle Aged; Recurrence; Remission Induction; Survival Analysis; Thalidomide; Treatment Outcome; Vidarabine | 2017 |
Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial).
Topics: Aged; Antineoplastic Agents; Chlorambucil; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Survival Analysis; Thalidomide | 2017 |
Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Agents; B7-1 Antigen; Cytokines; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Activation; Male; Middle Aged; Syndrome; Thalidomide; Time Factors; Up-Regulation | 2009 |
Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway.
Topics: Adjuvants, Immunologic; Aged; Antineoplastic Agents; B-Lymphocytes; BH3 Interacting Domain Death Agonist Protein; CD40 Ligand; Cells, Cultured; DNA-Binding Proteins; Female; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Immunophenotyping; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Proteins; NFATC Transcription Factors; Nuclear Proteins; Phosphatidylinositol 3-Kinases; Receptors, TNF-Related Apoptosis-Inducing Ligand; RNA Stability; RNA, Messenger; RNA, Neoplasm; Signal Transduction; Thalidomide; TNF-Related Apoptosis-Inducing Ligand; Tumor Protein p73; Tumor Suppressor Proteins | 2010 |
Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics.
Topics: Adult; Aged; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 17; Cytogenetics; Disease-Free Survival; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Prognosis; Recurrence; Risk; Thalidomide; Treatment Outcome | 2010 |
Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Dose-Response Relationship, Drug; Female; Gene Expression Profiling; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Remission Induction; Survival Rate; Thalidomide; Treatment Outcome | 2011 |
Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Female; Humans; Immunity, Cellular; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Risk Factors; Thalidomide; Treatment Outcome | 2011 |
The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Thalidomide; Treatment Outcome | 2011 |
Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Subsets; Male; Neoadjuvant Therapy; Thalidomide | 2011 |
Inflammation, TNFα and endothelial dysfunction link lenalidomide to venous thrombosis in chronic lymphocytic leukemia.
Topics: Adult; Aged; Blood Coagulation; Endothelium, Vascular; Female; Humans; Inflammation; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prospective Studies; Risk Factors; Thalidomide; Tumor Necrosis Factor-alpha; Up-Regulation; Venous Thrombosis | 2011 |
Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Allopurinol; Antimetabolites, Antineoplastic; Dose-Response Relationship, Immunologic; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Recurrence; Salvage Therapy; Thalidomide; Thrombocytopenia; Tumor Lysis Syndrome; Vidarabine | 2012 |
Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response.
Topics: B7-1 Antigen; B7-2 Antigen; CD40 Ligand; Cytokines; Humans; Immunophenotyping; Killer Cells, Natural; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Activation; MAP Kinase Signaling System; Thalidomide; Up-Regulation | 2011 |
Downregulation of BCL2 by AT-101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent manner.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Down-Regulation; Female; Gene Expression Regulation, Leukemic; Gossypol; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Proto-Oncogene Proteins c-bcl-2; Rituximab; Thalidomide; Tumor Cells, Cultured | 2012 |
Phase I study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukaemia: maintaining immune functions during therapy-induced immunosuppression.
Topics: Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Immunosuppression Therapy; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Thalidomide | 2012 |
Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fever; Humans; Immunologic Factors; Infections; Kaplan-Meier Estimate; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Recurrence; Rituximab; Salvage Therapy; Thalidomide; Time Factors; Treatment Outcome | 2013 |
Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Fatigue; Female; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Remission Induction; Thalidomide; Thrombocytopenia | 2006 |
Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow; Cytokines; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Remission Induction; T-Lymphocytes; Thalidomide | 2008 |
52 other study(ies) available for lenalidomide and Leukemia, Lymphocytic, Chronic, B-Cell
| Article | Year |
|---|---|
Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia.
Topics: Humans; Immunotherapy, Adoptive; Interleukin Receptor Common gamma Subunit; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; T-Lymphocytes; Tumor Microenvironment | 2022 |
Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trial.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Dexamethasone; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Treatment Outcome | 2020 |
Molecular Remission Using Low-Dose Immunotherapy with Minimal Toxicities for Poor Prognosis IGHV- Unmutated Chronic Lymphocytic Leukemia.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Female; Humans; Immunologic Factors; Immunotherapy; Interleukin-2; Killer Cells, Natural; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Piperidines; Precision Medicine; Prognosis; Remission Induction; Sulfonamides | 2020 |
IRF4 modulates the response to BCR activation in chronic lymphocytic leukemia regulating IKAROS and SYK.
Topics: Antineoplastic Agents; Cell Line; Cell Line, Tumor; Down-Regulation; Humans; Ikaros Transcription Factor; Interferon Regulatory Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Receptors, Antigen, B-Cell; Signal Transduction; Spleen; Syk Kinase | 2021 |
Lenalidomide abrogates the survival effect of bone marrow stromal cells in chronic lymphocytic leukemia.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Bone Marrow; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged | 2021 |
Lenalidomide maintenance in high risk chronic lymphocytic leukaemia: practice changing study or hypothesis generating approach?
Topics: Antineoplastic Agents; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Thalidomide | 2017 |
LenD: a study to establish the safety and efficacy of lenalidomide and dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Recurrence; Retreatment; Treatment Outcome | 2018 |
Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged | 2018 |
Gene mutations in lenalidomide-treated CLL.
Topics: Genes, Neoplasm; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Thalidomide | 2018 |
Lenalidomide can be safely combined with chlorambucil and rituximab in older patients with chronic lymphocytic leukemia.
Topics: Aged; Chlorambucil; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Treatment Outcome | 2019 |
Ig-Like Transcript 2 (ILT2) Blockade and Lenalidomide Restore NK Cell Function in Chronic Lymphocytic Leukemia.
Topics: Aged; Antibodies, Blocking; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Cells, Cultured; Chromosome Deletion; Drug Synergism; Female; Humans; Immunologic Factors; Killer Cells, Natural; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocyte Immunoglobulin-like Receptor B1; Male; Middle Aged | 2018 |
Population pharmacokinetics of lenalidomide in patients with B-cell malignancies.
Topics: Administration, Oral; Adult; Aged; B-Lymphocytes; Biological Availability; Clinical Trials, Phase I as Topic; Creatinine; Datasets as Topic; Dose-Response Relationship, Drug; Female; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Male; Middle Aged; Models, Biological; Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Renal Elimination; Young Adult | 2019 |
Non-Hodgkin's lymphomas, version 1.2013.
Topics: Antineoplastic Agents; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis C; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Thalidomide; Virus Activation | 2013 |
T cells in CLL: lost in migration.
Topics: Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Function-Associated Antigen-1; rho GTP-Binding Proteins; Signal Transduction; T-Lymphocytes; Thalidomide | 2013 |
Jump-starting the T cells in CLL.
Topics: Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Humans; Immunological Synapses; Immunotherapy; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; T-Lymphocytes; Thalidomide | 2013 |
Lenalidomide as first-line therapy for elderly CLL patients.
Topics: Aged; Angiogenesis Inhibitors; Clinical Trials, Phase II as Topic; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Thalidomide | 2013 |
Lenalidomide-induced graft-vs.-Leukemia effect in a patient with chronic lymphocytic leukemia who relapsed after allogeneic stem cell transplant.
Topics: Aged; Bone Marrow; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphatic Diseases; Male; Positron-Emission Tomography; Recurrence; Thalidomide; Tomography, X-Ray Computed; Transplantation, Homologous | 2014 |
Chemotherapy-induced augmentation of T cells expressing inhibitory receptors is reversed by treatment with lenalidomide in chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Gene Expression Regulation, Leukemic; Humans; Induction Chemotherapy; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Receptors, Immunologic; T-Lymphocytes; Thalidomide | 2014 |
Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Chromosomes, Human, Pair 17; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Retrospective Studies; Rituximab; Smith-Magenis Syndrome; Thalidomide; Treatment Outcome | 2014 |
Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Immunophenotyping; Kaplan-Meier Estimate; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Receptors, Fc; Risk Factors; Rituximab; Thalidomide; Treatment Outcome | 2014 |
Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53.
Topics: Adaptor Proteins, Signal Transducing; Angiogenesis Inhibitors; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Gene Expression Regulation, Leukemic; HeLa Cells; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Peptide Hydrolases; Signal Transduction; Thalidomide; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Ubiquitin-Protein Ligases | 2014 |
Lenalidomide, an antiproliferative CLL drug.
Topics: Adaptor Proteins, Signal Transducing; Angiogenesis Inhibitors; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Peptide Hydrolases; Thalidomide; Ubiquitin-Protein Ligases | 2014 |
Lenalidomide induces immunomodulation in chronic lymphocytic leukemia and enhances antitumor immune responses mediated by NK and CD4 T cells.
Topics: Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Apoptosis; CD4-Positive T-Lymphocytes; Cell Proliferation; Humans; Immunomodulation; Interleukin-2; Killer Cells, Natural; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Subsets; Thalidomide; Tumor Cells, Cultured | 2014 |
Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia.
Topics: Actin Cytoskeleton; Angiogenesis Inhibitors; Apoptosis; Biomarkers, Tumor; Blotting, Western; Cell Adhesion; Cell Movement; Cell Proliferation; Coculture Techniques; Female; Flow Cytometry; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunophenotyping; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Activation; Macrophages; Monocytes; Phagocytosis; Thalidomide; Tumor Cells, Cultured; Tumor Microenvironment | 2015 |
Lenalidomide differently modulates CD20 antigen surface expression on chronic lymphocytic leukemia B-cells.
Topics: Antigens, CD20; Antineoplastic Agents; Cell Membrane; Gene Expression Regulation, Leukemic; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Thalidomide | 2015 |
Chemotherapy of mantle cell lymphoma relapsed or refractory chronic lymphocytic leukaemia.
Topics: Adenine; Antineoplastic Agents; Bendamustine Hydrochloride; Bortezomib; Chromosomes, Human, Pair 17; Cytarabine; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Mutation; Neoplasm Recurrence, Local; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Sirolimus; Thalidomide; Tumor Suppressor Protein p53; Vidarabine | 2016 |
Lenalidomide Induces Interleukin-21 Production by T Cells and Enhances IL21-Mediated Cytotoxicity in Chronic Lymphocytic Leukemia B Cells.
Topics: B-Lymphocytes; Cell Line, Tumor; Cytotoxicity, Immunologic; Gene Expression Profiling; Humans; Immunologic Factors; Interleukins; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Specific Protein Tyrosine Kinase p56(lck); Phospholipase C gamma; Phosphorylation; Receptors, Interleukin-21; Syk Kinase; T-Lymphocytes; Thalidomide | 2016 |
Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug.
Topics: Actins; Animals; Antigen Presentation; Antineoplastic Agents; B-Lymphocytes; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Humans; Immunologic Factors; Interleukin-2; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Activation; Lymphocyte Culture Test, Mixed; Lymphocyte Function-Associated Antigen-1; Lymphocyte Specific Protein Tyrosine Kinase p56(lck); Mice; Mice, Inbred Strains; Mice, Transgenic; Microfilament Proteins; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Receptors, Antigen, T-Cell; Superantigens; T-Lymphocytes; T-Lymphocytes, Cytotoxic; Thalidomide | 2008 |
Concurrent B-cell chronic lymphocytic leukemia and multiple myeloma treated successfully with lenalidomide.
Topics: Aged; Antineoplastic Agents; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Multiple Myeloma; Neoplasms, Multiple Primary; Thalidomide | 2009 |
Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antibody-Dependent Cell Cytotoxicity; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cytotoxicity, Immunologic; Down-Regulation; Drug Antagonism; Drug Delivery Systems; Endocytosis; Female; Genetic Therapy; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Liposomes; Male; Middle Aged; Rituximab; Thalidomide; Tumor Cells, Cultured | 2008 |
Lenalidomide-associated tumor flare reaction is manageable in patients with chronic lymphocytic leukemia.
Topics: Antineoplastic Agents, Alkylating; Dose-Response Relationship, Drug; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Thalidomide; Tumor Lysis Syndrome | 2008 |
50th ASH Annual Meeting.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Nadroparin; Rituximab; Thalidomide; Thromboembolism; Uric Acid | 2009 |
The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; B-Lymphocytes; CD40 Antigens; Cytotoxicity Tests, Immunologic; Flow Cytometry; Humans; Killer Cells, Natural; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Thalidomide; Tumor Cells, Cultured | 2009 |
E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction.
Topics: Animals; Disease Models, Animal; Disease Progression; Gene Expression Profiling; Humans; Immunological Synapses; Immunotherapy; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Mice, Transgenic; Proto-Oncogene Proteins; Signal Transduction; T-Lymphocytes; Thalidomide | 2009 |
Lenalidomide treatment of chronic lymphocytic leukaemia patients reduces regulatory T cells and induces Th17 T helper cells.
Topics: Antineoplastic Agents; Humans; Interleukin-17; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; T-Lymphocytes, Helper-Inducer; T-Lymphocytes, Regulatory; Thalidomide | 2010 |
New agents for the treatment of genetically high-risk chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Cyclophosphamide; Drug Therapy; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Medical Oncology; Risk; Rituximab; Thalidomide; Treatment Outcome; Vidarabine | 2010 |
Immunomodulators in chronic lymphocytic leukemia: where does lenalidomide belong?
Topics: Animals; Antineoplastic Agents; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Thalidomide | 2010 |
The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Cell Line, Tumor; Class Ia Phosphatidylinositol 3-Kinase; Enzyme Activation; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Phosphoinositide-3 Kinase Inhibitors; Purines; Quinazolinones; RNA, Small Interfering; Thalidomide | 2011 |
Dermatological complications following initiation of lenalidomide in a patient with chronic lymphocytic leukaemia.
Topics: Erythema; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Sweet Syndrome; Thalidomide | 2011 |
Lenalidomide in CLL: what is the optimal dose?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Thalidomide; Treatment Outcome | 2011 |
Lenalidomide can be highly effective in chronic lymphocytic leukaemia despite T-cell depletion and deletion of chromosome 17p.
Topics: Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 17; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Depletion; T-Lymphocytes; Thalidomide | 2011 |
Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Clinical Trials as Topic; Cytokines; Female; Humans; Immunologic Factors; Immunophenotyping; Interleukin-2; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; T-Lymphocyte Subsets; Thalidomide | 2011 |
Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer.
Topics: Actins; Antibodies, Neoplasm; Antigen-Presenting Cells; Antigens, CD; Antineoplastic Agents; Down-Regulation; Enzyme Activation; Humans; Immune Evasion; Immunologic Factors; Immunological Synapses; Immunosuppression Therapy; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Ligands; Polymerization; Prognosis; rho GTP-Binding Proteins; Signal Transduction; T-Lymphocytes; Thalidomide; Up-Regulation | 2012 |
Long-term molecular remission with lenalidomide treatment of relapsed chronic lymphocytic leukemia.
Topics: Adult; Antineoplastic Agents; Complementarity Determining Regions; Gene Rearrangement, B-Lymphocyte, Heavy Chain; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neoplasm, Residual; Recurrence; Remission Induction; Thalidomide; Time Factors; Young Adult | 2013 |
Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; cdc42 GTP-Binding Protein; Cell Movement; Coculture Techniques; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Function-Associated Antigen-1; Peptide Hydrolases; Primary Cell Culture; rac1 GTP-Binding Protein; rho GTP-Binding Proteins; rhoA GTP-Binding Protein; Signal Transduction; T-Lymphocytes; Thalidomide; Tumor Cells, Cultured; Ubiquitin-Protein Ligases | 2013 |
Lenalidomide reduces survival of chronic lymphocytic leukemia cells in primary cocultures by altering the myeloid microenvironment.
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow; Cell Survival; Coculture Techniques; Drug Evaluation, Preclinical; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Myeloid Cells; Primary Cell Culture; Thalidomide; Tumor Cells, Cultured; Tumor Microenvironment | 2013 |
45th Annual Meeting of the American Society of Hematology December 6-9, 2003.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Hematology; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Multicenter Studies as Topic; Multiple Myeloma; Oxides; Prognosis; Protein-Tyrosine Kinases; Recurrence; Risk; Rituximab; Salvage Therapy; Thalidomide; Time Factors; ZAP-70 Protein-Tyrosine Kinase | 2004 |
Advances in the treatment of MDS, multiple myeloma, and CLL.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Monitoring; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Multiple Myeloma; Myelodysplastic Syndromes; Nurse's Role; Oncology Nursing; Prognosis; Pyrazines; Risk Assessment; Thalidomide | 2007 |
Tumor lysis syndrome/tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Thalidomide; Tumor Lysis Syndrome | 2007 |
Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Cytotoxicity, Immunologic; Dendritic Cells; Drug Interactions; Immunohistochemistry; Immunosuppressive Agents; Killer Cells, Natural; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Mice, SCID; Microcirculation; Neovascularization, Pathologic; Rituximab; Thalidomide | 2008 |
Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia.
Topics: Adult; Antineoplastic Agents; Apoptosis; Dose-Response Relationship, Drug; Flow Cytometry; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Rate; Thalidomide; Tumor Cells, Cultured | 2008 |
Rapid resolution of Mycobacterium marinum chronic skin infection during lenalidomide therapy for chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mycobacterium Infections, Nontuberculous; Mycobacterium marinum; Skin; Skin Diseases, Bacterial; Thalidomide | 2008 |